Rigel Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 11, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	634	296	253	259	453	591
Market Cap Growth	65.76%	17.18%	-2.48%	-42.79%	-23.38%	64.89%
Enterprise Value	558	335	295	269	403	560
Last Close Price	34.94	16.82	14.50	15.00	26.50	35.00
PE Ratio	5.64	16.95	-	-	-	-
Forward PE	7.79	17.39	-	-	-	-
PS Ratio	2.21	1.65	2.18	2.24	3.27	5.45
PB Ratio	5.39	90.11	-8.83	-19.04	14.92	17.38
P/TBV Ratio	6.87	-	-	-	14.92	17.38
P/FCF Ratio	9.31	9.43	-	-	86.30	-
P/OCF Ratio	9.30	9.41	-	-	77.10	-
EV/Sales Ratio	1.98	1.87	2.55	2.33	2.90	5.15
EV/EBITDA Ratio	4.60	12.69	-	-	-	-
EV/EBIT Ratio	4.69	13.86	-	-	-	-
EV/FCF Ratio	8.19	10.67	-	-	76.67	-
Debt / Equity Ratio	0.52	30.40	-3.64	-6.44	3.01	1.15
Debt / EBITDA Ratio	0.50	3.68	-	-	-	-
Debt / FCF Ratio	0.89	3.18	-	-	17.38	-
Asset Turnover	1.48	1.27	0.92	0.77	1.00	0.84
Inventory Turnover	3.31	5.49	2.76	5.17	10.82	12.21
Quick Ratio	1.94	1.88	1.64	1.51	2.21	1.80
Current Ratio	2.28	2.13	1.86	1.78	2.43	2.18
Return on Equity (ROE)	220.06%	-	-	-699.04%	-55.63%	-67.72%
Return on Assets (ROA)	38.93%	10.75%	-10.68%	-24.34%	-8.77%	-14.04%
Return on Invested Capital (ROIC)	310.42%	103.51%	-124.52%	-932.00%	-312.65%	-739.58%
Return on Capital Employed (ROCE)	80.30%	24.00%	-33.60%	-85.00%	-18.80%	-41.70%
Earnings Yield	17.86%	5.90%	-9.92%	-22.59%	-3.95%	-5.03%
FCF Yield	10.74%	10.61%	-2.27%	-28.62%	1.16%	-9.04%
Buyback Yield / Dilution	-4.06%	-1.64%	-2.07%	0.00%	-1.03%	-0.81%

Updated Nov 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q